Ashley McEvoy
Director at PG
Board
About Ashley McEvoy
Ashley McEvoy is an independent director of Procter & Gamble and President/CEO of Insulet Corporation (public medtech) since April 2025. She previously served as Executive Vice President, Worldwide Chairman of MedTech at Johnson & Johnson (2018–2023) after multiple senior operating roles across consumer medical devices and vision care; earlier career includes leadership in consumer health and advertising. Age 53 as reported in P&G’s 2024 proxy; appointed to P&G’s board on December 12, 2023; currently serves on the Compensation & Leadership Development (C&LD) and Innovation & Technology (I&T) Committees. Her board profile highlights leadership/strategy, global healthcare operating experience, marketing, and innovation/digital acumen.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Johnson & Johnson | EVP, Worldwide Chairman, MedTech | 2018–2023 | Led surgery, orthopaedics, interventional solutions, eye health globally; recognized for transformative innovation and digital capability build-outs. |
| Johnson & Johnson | Company Group Chairman, Consumer Medical Devices | 2014–2018 | Global leadership across consumer medical devices. |
| Johnson & Johnson | Company Group Chairman, Vision Care | 2012–2014 | Global business leadership. |
| Johnson & Johnson | Worldwide President, Ethicon (Sutures) | 2009–2011 | Led global suture products business. |
| Johnson & Johnson | President, McNeil Consumer Healthcare | 2006–2009 | P&L leadership in consumer health. |
| Johnson & Johnson | VP Marketing & GM, McNeil Labs | 2003–2006 | Marketing/GM leadership. |
| Grey Advertising; J. Walter Thompson | Advertising/Brand roles | Pre-1996 | Early career in marketing. |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Insulet Corporation (Public) | President & CEO; Director | Since Apr 2025 | Current operating role; listed as other public company board. |
| Children’s Hospital of Philadelphia | Board of Trustees (prior service) | N/A | Non-profit governance experience. |
Board Governance
- Committee assignments: C&LD Committee member; I&T Committee member (not a chair). FY 2024–25 committee meetings: C&LD (5), I&T (2); Board held 6 meetings. Average attendance among incumbents ~98%; none attended <75%. All four standing committees are fully independent.
- Independence: Board determined all nominees except Moeller/Jejurikar are independent under NYSE standards and P&G Independence Guidelines (committees composed entirely of independent directors).
- Executive sessions: Independent directors, led by the Lead Director, met eight times in executive session in FY 2024–25.
- Time commitments policy: Active public-company CEOs may sit on no more than one additional outside public board (including their own company board); McEvoy’s Insulet CEO role plus one P&G board seat conforms.
Fixed Compensation (Director)
| Fiscal Year | Annual Retainer ($) | Committee/Lead Fees ($) | Fees Taken as Common Stock ($) | RSU Grant ($) | Total ($) |
|---|---|---|---|---|---|
| FY 2024–25 | 120,000 | — | 115,000 (grant-date fair value $115,423) | 220,000 | 340,000 |
| FY 2023–24 (pro‑rated) | 66,247 | — | 55,000 (grant-date fair value $55,246) | 181,923 (pro‑rated RSUs) | 248,170 |
Key terms:
- Standard non-employee director pay: $120,000 annual cash retainer; annual RSU grant $220,000; additional retainers for Lead Director/Chairs (none applicable to McEvoy). Directors may elect fees in cash, RSUs, or unrestricted stock. Ownership guideline: 6x annual retainer within five years; all non-employee directors meet or are on track.
- RSU vesting/settlement: Annual RSUs vest after one year; generally settle after leaving the board; beginning with Oct 2025 grant, settlement at one-year service date with option to defer to post‑board service.
Performance Compensation
- Not applicable for directors: P&G discloses cash retainers and time‑based RSUs for directors; no performance-conditioned director awards or metrics disclosed.
Other Directorships & Interlocks
| Category | Details |
|---|---|
| Current public boards | Insulet Corporation (since Apr 2025). |
| P&G C&LD Committee interlocks | None; all C&LD members (including McEvoy) independent; no interlocks with other entities. |
Expertise & Qualifications
- Leadership/strategy/risk: Broad P&L leadership across global medtech and consumer health businesses.
- Marketing/consumer industry: Early career in advertising; extensive consumer healthcare brand management.
- Innovation/digital: Recognized for driving innovation platforms and enhancing in‑house digital capabilities with leading tech partners.
Equity Ownership
| As of June 30, 2025 | Direct & Plan Shares | RSUs Outstanding (beneficial ownership table) | Unvested Annual RSUs Outstanding | Notes |
|---|---|---|---|---|
| Ashley McEvoy | 1,009 shares | 2,627 RSUs | 1,334 unvested RSUs from Oct 8, 2024 grant + dividend equivalents (general for all directors except Arnold) | Director ownership guideline = 6x retainer; directors meet or are on track within 5 years. |
- Hedging/pledging: P&G insider trading policy prohibits directors from hedging, short sales, pledging, collars, or other derivative transactions in company stock.
- Related-party/pledged shares: No related-party transactions disclosed for directors other than a separate management example; none currently proposed.
Insider Trades (Form 4 highlights – McEvoy at PG)
| Filing Date | Transaction Date | Type | Shares | Post-Transaction Ownership | SEC Link |
|---|---|---|---|---|---|
| 2025-10-15 | 2025-10-14 | Award (A) | 1,475 | 5,318.0241 | https://www.sec.gov/Archives/edgar/data/80424/000008042425000228/0000080424-25-000228-index.htm |
| 2025-09-10 | 2025-09-09 | Award (A) | 189 | 3,843.0241 | https://www.sec.gov/Archives/edgar/data/80424/000008042425000150/0000080424-25-000150-index.htm |
- Source: SEC Form 4 records retrieved 2023-12-01 to 2025-11-20; transactions reflect director equity awards and resulting beneficial ownership updates.
Governance Assessment
-
Strengths
- Independence and active engagement: Independent director with committee service on C&LD and I&T; board and committee structure demonstrates robust oversight with independent committees and frequent executive sessions (eight in FY 2024–25). Average director attendance ~98%; none below 75%.
- Compensation alignment for directors: Simple, transparent structure (cash retainer + time‑based RSUs) with meaningful stock ownership guideline (6x retainer) and prohibitions on hedging/pledging, supporting alignment with shareholders.
- Human capital and innovation oversight: C&LD leverages independent consultant; I&T focuses on product/package superiority and technology risks—McEvoy’s medtech and digital experience is additive.
- Shareholder environment: Say‑on‑pay approval of 90.65% at 2024 meeting and ongoing investor engagement support governance stability.
-
Watch‑items / potential risks
- External CEO role and time commitments: As Insulet’s CEO, outside board limits apply; P&G policy caps active CEOs at one additional public board—McEvoy’s service complies, but workload remains a monitoring point for board effectiveness.
- Ownership scale: Beneficial ownership is modest in absolute terms given director tenure; continuing RSU accrual and 6x retainer guideline should improve alignment over time (within five‑year window).
- Conflicts/related party: No P&G‑related transactions disclosed for McEvoy; policy and Audit Committee review provide controls—continue to monitor in light of her external operating role.
Overall, McEvoy brings relevant operating expertise in healthcare, innovation, and marketing to P&G’s C&LD and I&T committees with clean independence, strong governance scaffolding (ownership, anti‑hedging/pledging, no interlocks), and active board processes; primary investor focus should be on ongoing bandwidth/time‑commitment given concurrent public‑company CEO duties and continued build of share ownership per guideline.